jbog -completely agree
if they have such a strong conviction on Copaxone FDA approval and launch at least by 2014, why the F don't they deploy at least 150m of that cash to work in buying back shares ?
if you think about it, even if you are overly conservative ML with TL and 80m cash(copaxone expense for 3 years), will be sustainable enterprise(Zero loss). I believe about 25m of expense is related to copaxoxne and that will not be there in 2-3 years time frame. So even without copaxone launch, and with a 3rd entrant in Lovenox, they will be sustainable enterprise.
FOB - all the while they have been saying they are looking for a deal where they not only get a fair share but they are expecting partner to get capital